N-Nitroso Brivaracetam Methyl Ester Impurity
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

N-Nitroso Brivaracetam Methyl Ester Impurity

● In Stock

Catalogue No.:VE0024398
CAS No.:N/A
Mol. Formula:C12H23N3O4
Mol. Weight:273.33 g/mol

Additional information on N-Nitroso Brivaracetam Methyl Ester Impurity

Parent drug

Brivaracetam

IUPAC Name

(R)-methyl 3-((((S)-1-amino-1-oxobutan-2-yl)(nitroso)amino)methyl)hexanoate

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

CCC[C@@H](CN([C@@H](CC)C(N)=O)N=O)CC(OC)=O

InChI

InChI=1S/C12H23N3O4/c1-4-6-9(7-11(16)19-3)8-15(14-18)10(5-2)12(13)17/h9-10H, 4-8H2, 1-3H3, (H2, 13, 17)/t9-, 10+/m1/s1

Description

N-Nitroso Brivaracetam Methyl Ester Impurity is an N-nitroso derivative of the secondary amine present in Brivaracetam | which is a highly characterized reference material that meets stringent regulatory standards set for nitrosamine compounds | including those set by USP | EMA | JP | and BP. This nitroso standard is essential for a variety of applications | such as analytical method development | method validation (AMV) | and Quality Control (QC) | particularly in the context of Brivaracetam production. It is suitable for use in both Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). This nitrosamine standard helps establish detection limits | quantify impurity levels | and ensure trace nitroso impurities in pharmaceutical products remain within FDA and EMA safety limits.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url